Zomedica Pharmaceuticals Corp Stock Analysis

Zomedica Stock Analysis Notes

The company has Price to Book (P/B) ratio of 0.6. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zomedica Pharmaceuticals recorded a loss per share of 0.06. The entity had not issued any dividends in recent years. Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 47 people. For more information please call Robert Cohen at 734 369 2555 or visit https://www.zomedica.com.

Zomedica Pharmaceuticals Investment Alerts

Zomedica Pharmaceuticals Upcoming and Recent Events

Zomedica Largest EPS Surprises

View All Earnings Estimates

Zomedica Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 147.6 M.

Zomedica Profitablity

The company has Net Profit Margin of (2.15) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (1.47) %, which entails that for every $100 of revenue, it lost $1.47.

Management Efficiency

Zomedica Pharmaceuticals has Return on Asset of (0.0929) % which means that on every $100 spent on assets, it lost $0.0929. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2392) %, meaning that it generated no profit with money invested by stockholders. Zomedica Pharmaceuticals' management efficiency ratios could be used to measure how well Zomedica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Zomedica Pharmaceuticals' Intangible Assets are very stable compared to the past year. As of the 13th of December 2024, Intangibles To Total Assets is likely to grow to 0.48, while Net Current Asset Value is likely to drop about 113.7 K.

Technical Drivers

As of the 13th of December 2024, Zomedica Pharmaceuticals maintains the Mean Deviation of 1.76, market risk adjusted performance of (0.09), and Standard Deviation of 3.93. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zomedica Pharmaceuticals Corp, as well as the relationship between them. Please check out Zomedica Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Zomedica Pharmaceuticals is priced fairly, providing market reflects its latest price of 0.123 per share. As Zomedica Pharmaceuticals appears to be a penny stock we also urge to confirm its jensen alpha numbers.

Zomedica Pharmaceuticals Price Movement Analysis

Zomedica Pharmaceuticals Insider Trading Activities

Zomedica Pharmaceuticals Outstanding Bonds

Zomedica Pharmaceuticals Predictive Daily Indicators

Zomedica Pharmaceuticals Forecast Models

Zomedica Pharmaceuticals' time-series forecasting models are one of many Zomedica Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zomedica Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Zomedica Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zomedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Zomedica Pharmaceuticals. By using and applying Zomedica Stock analysis, traders can create a robust methodology for identifying Zomedica entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zomedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zomedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Zomedica Pharmaceuticals Corp stock analysis indicators help investors evaluate how Zomedica Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Zomedica Pharmaceuticals shares will generate the highest return on investment. By understating and applying Zomedica Pharmaceuticals stock analysis, traders can identify Zomedica Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.